Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study.
Secondary hyperparathyroidism can develop as a result of bone metastases from prostatic cancer, but this has not been studied from the multiple aspects of biochemistry, hormonal status and histomorphometry. In 20 patients with stage-D prostatic cancer, a transiliac bone biopsy was performed for histomorphometric study. In all of them, molecular parathormone (PTH-M) and osteocalcin were determined by radioimmunoassay together with other parameters considered to be biological markers of bone remodelling. Of these 20 patients, only 2 (10%) had elevated PTH-M (240 +/- 20.6 pmol/l), differing significantly from the other 18 (58.6 +/- 11.7 pmol/l) and from controls (60.4 +/- 7.2 pmol/l). In the high PTH-M patients, corrected calcium was low (7.8 +/- 0.4 mg/dl) as compared to normal PTH-M patients (9.2 +/- 0.5 mg/dl, p less than 0.001), and this was also the case for serum phosphorus (2.2 +/- 0.6 vs. 3.2 +/- 0.3 and 3.4 +/- 0.4 mg/dl, respectively p less than 0.001). Alkaline phosphatase was raised in the patient groups as compared to controls (p less than 0.001) and was higher in the high PTH-M group (362 +/- 58 vs. 224 +/- 62 U/l, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Rico
H
H
Department of Medicine, Medical School, University of Alcalá de Henares, Madrid, Spain.
Uson
A
A
Hernandez
E R
ER
Prados
P
P
Paramo
P
P
Cabranes
J A
JA
D001859:Bone Neoplasms / Q000150:complications / Q000473:pathology / Q000556:secondary*; D002277:Carcinoma / Q000150:complications / Q000473:pathology / Q000556:secondary*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000378:metabolism*; D008297:Male; D015675:Osteocalcin / Q000032:analysis; D010281:Parathyroid Hormone / Q000032:analysis; D011471:Prostatic Neoplasms
D010281:Parathyroid Hormone; D015675:Osteocalcin